

Nicolas Jacquelot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7315589/publications.pdf>

Version: 2024-02-01

39
papers

8,910
citations

331670

21
h-index

315739

38
g-index

44
all docs

44
docs citations

44
times ranked

12644
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	12.6	3,689
2	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015, 350, 1079-1084.	12.6	2,539
3	<i>Enterococcus hirae</i> and <i>Barnesiella intestinihominis</i> Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , 2016, 45, 931-943.	14.3	645
4	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016, 30, 147-160.	16.8	410
5	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. <i>Cancer Research</i> , 2015, 75, 3800-3811.	0.9	201
6	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019, 29, 846-861.	12.0	160
7	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	12.0	143
8	The neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity. <i>Nature Immunology</i> , 2020, 21, 168-177.	14.5	133
9	Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. <i>Nature Immunology</i> , 2021, 22, 851-864.	14.5	97
10	Mature Cytotoxic CD56 ^{bright} /CD16 ⁺ Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma. <i>Cancer Research</i> , 2014, 74, 81-92.	0.9	85
11	TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. <i>Oncolmmunology</i> , 2018, 7, e1462431.	4.6	82
12	Innate lymphoid cells and cancer. <i>Nature Immunology</i> , 2022, 23, 371-379.	14.5	75
13	Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. <i>Blood</i> , 2020, 136, 3004-3017.	1.4	71
14	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 921-937.	8.2	71
15	Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 2480.	4.8	57
16	Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. <i>Oncolmmunology</i> , 2021, 10, 1900508.	4.6	57
17	Regulation of CD4 ⁺ NKG2D ⁺ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15 and NKG2D Triggering. <i>Cancer Research</i> , 2014, 74, 68-80.	0.9	43
18	Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity. <i>Cancer Research</i> , 2021, 81, 5555-5571.	0.9	35

#	ARTICLE	IF	CITATIONS
19	Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival. <i>Cancers</i> , 2021, 13, 559.	3.7	31
20	Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 994-1001.	0.7	27
21	Physiological Regulation of Innate Lymphoid Cells. <i>Frontiers in Immunology</i> , 2019, 10, 405.	4.8	21
22	NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution. <i>Oncolmmunology</i> , 2016, 5, e1154251.	4.6	20
23	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. <i>Oncolmmunology</i> , 2017, 6, e1299303.	4.6	20
24	Type 1 conventional dendritic cell fate and function are controlled by DC-SCRIPT. <i>Science Immunology</i> , 2021, 6, .	11.9	19
25	Sensing of physiological regulators by innate lymphoid cells. <i>Cellular and Molecular Immunology</i> , 2019, 16, 442-451.	10.5	14
26	Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword. <i>Frontiers in Immunology</i> , 2019, 10, 3080.	4.8	14
27	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
28	Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5967.	3.7	11
29	Immunodynamics of explanted human tumors for immuno—oncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	6.9	9
30	Deconstructing deployment of the innate immune lymphocyte army for barrier homeostasis and protection. <i>Immunological Reviews</i> , 2018, 286, 6-22.	6.0	8
31	Neuroimmune Interactions and Rhythmic Regulation of Innate Lymphoid Cells. <i>Frontiers in Neuroscience</i> , 2021, 15, 657081.	2.8	8
32	Tissue-resident lymphocytes: weaponized sentinels at barrier surfaces. <i>F1000Research</i> , 2020, 9, 691.	1.6	8
33	Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9044.	4.1	7
34	Type 2 innate lymphoid cells: a novel actor in anti-melanoma immunity. <i>Oncolmmunology</i> , 2021, 10, 1943168.	4.6	5
35	Innate Lymphoid Cells: Role in Immune Regulation and Cancer. <i>Cancers</i> , 2022, 14, 2071.	3.7	5
36	Reply to —Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma—™. <i>Nature Communications</i> , 2018, 9, 2922.	12.8	3

#	ARTICLE	IF	CITATIONS
37	Differential requirement for the Polycomb repressor complex 2 in dendritic cell and tissue-resident myeloid cell homeostasis. <i>Science Immunology</i> , 2021, 6, eabf7268.	11.9	3
38	Editorial: Innate Lymphoid Cells in Cancer: Friends or Foes?. <i>Frontiers in Immunology</i> , 2021, 12, 804156.	4.8	0
39	A protocol to isolate bone marrow innate lymphoid cells for alymphoid mouse reconstitution. <i>STAR Protocols</i> , 2022, 3, 101534.	1.2	0